COMPARISON / RESEARCH PEPTIDE FUNDAMENTALS
Three Research Peptides, Three Evidence Profiles
BPC-157, retatrutide, and tesamorelin come from different parts of the research landscape. This page places them side by side on the dimensions that matter for reading the literature clearly.
The short version
This desk covers three research peptides that sit at very different points on the evidence spectrum. BPC-157 has the deepest preclinical record but the thinnest human file — three small pilot studies as of 2025. Retatrutide has the most human clinical evidence here, from multiple Phase 2 randomized controlled trials with hundreds of participants, but it is still investigational and unapproved anywhere. Tesamorelin is the only compound on this desk with FDA approval, but that approval is narrow: one specific condition, one specific population. Reading them together clarifies what it means for a peptide to have "evidence" — and how much that can vary.
Side-by-side comparison
| Feature | BPC-157 | Retatrutide | Tesamorelin |
|---|---|---|---|
| Class | Stable gastric pentadecapeptide; cytoprotective research peptide | Triple GIP/GLP-1/glucagon receptor agonist (investigational) | GHRH analogue; peptide hormone |
| Primary study area | Tissue repair, gut cytoprotection, angiogenesis | Obesity, type 2 diabetes, metabolic liver disease | HIV-associated lipodystrophy; visceral fat reduction |
| Key mechanism | VEGFR2-Akt-eNOS angiogenesis; FAK-paxillin cell migration | Simultaneous GIP/GLP-1/glucagon receptor agonism; energy expenditure + appetite suppression | GHRH-R agonism → pituitary GH release → lipolysis in visceral adipose |
| Species studied | Primarily rats; chick membrane; 2 human adults (safety pilot) | Humans (Phase 1b, Phase 2 RCTs), in vitro cryo-EM | Humans (RCTs, meta-analysis), healthy men |
| Evidence maturity | Preclinical dominant; 3 small human pilots [2] | Phase 2 completed; Phase 3 (TRIUMPH) ongoing [6][9] | Phase 3 completed; meta-analysis of 5 RCTs [13] |
| Strongest single human finding | 2 adults, IV pilot, no adverse events [1] | -24.2% body weight at 48 wk (Phase 2, n=338) [9] | VAT -27.71 cm² (meta-analysis, pooled RCTs) [13] |
| FDA status | Not approved; 503A compounding restriction | Investigational; Phase 3 ongoing; not approved | Approved for HIV-associated lipodystrophy only (NDA 022505, 2010) [14] |
| WADA status | Prohibited at all times (S0) | Not specifically prohibited (check current Prohibited List) | Prohibited in- and out-of-competition (S2 GHRH analogue) |
| Key caution | Single research-group dominance; no large human trials [2] | Unapproved; GI AEs; heart-rate increase; lean-mass loss [9] | Visceral fat reaccumulates on discontinuation; IGF-1 elevation; off-label only outside HIV [17] |
Reading the comparison
The table above maps the compounds across six dimensions, but a few things are worth stating plainly.
Evidence maturity is not the same as access or safety. Tesamorelin has the most mature evidence — completed Phase 3, meta-analyzed RCTs — but it is a prescription drug for one narrow indication. Retatrutide has the most current Phase 2 human data but is not approved anywhere and has a documented GI and heart-rate side-effect profile from those very trials [9]. BPC-157 has the longest preclinical record but the fewest human data points [2].
Mechanisms point in different directions. BPC-157 works peripherally, in the tissue, through vessel growth [4][5]. Tesamorelin works at the pituitary level, preserving normal GH pulsatility to drive fat breakdown [16]. Retatrutide works at three receptor systems in the gut and brain simultaneously, reducing both appetite and metabolic rate of fat storage while raising energy expenditure through the glucagon arm [7][9]. These are genuinely distinct mechanisms, not overlapping approaches to the same target.
The approval gap is informative. Tesamorelin reaching FDA approval for HIV lipodystrophy tells you something about how that specific evidence was accumulated and evaluated. Retatrutide not yet being approved — despite striking Phase 2 numbers — tells you something about what Phase 3 and regulatory review are designed to add. BPC-157 having no approval trajectory tells you something about where preclinical evidence stops and the costly, long road to human approval begins.